{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:21Z","timestamp":1783977201753,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: This study aimed to evaluate the effectiveness and drug retention rate of secukinumab (SCK) in axial spondyloarthritis (ax-SpA) within a multicentric real-life cohort. Methods: Data from patients with ax-SpA treated with SCK at five Italian centers were collected retrospectively, excluding those with a diagnosis of Psoriatic Arthritis. Evaluations were conducted at baseline and at 3, 6, 12, 18, and 24 months. Assessments included C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), BASDAI, and ASDAS-CRP. Results: Seventy-one ax-SpA patients (57.7% female, mean age: 53.86 \u00b1 12.67 years) were enrolled. Baseline mean BASDAI was 6.2 \u00b1 1.4 and ASDAS-CRP was 2.9 \u00b1 1.3. Significant improvements in BASDAI and ASDAS-CRP were observed over time, with BASDAI reducing to 3.5 \u00b1 1.9 (p &lt; 0.0001) and ASDAS-CRP to 1.7 \u00b1 0.9 (p &lt; 0.0001) at 24 months. The follow-up duration averaged 20.46 \u00b1 13.46 months. By the end of follow-up, 29.5% of patients discontinued SCK. The two-year retention rate was 72%. Dropout risk was higher in patients with fibromyalgia (HR: 2.896, p = 0.026). No significant retention differences were found based on sex, age, enthesitis, radiographic disease, combination with cDMARDs, SCK dosage, or previous bDMARD exposure. Lower ASDAS-CRP at the study\u2019s end was noted in patients without fibromyalgia (1.4 vs. 2.5, p &lt; 0.001). Conclusions: SCK showed rapid and lasting effectiveness for ax-SpA with a favorable retention rate, though fibromyalgia may reduce treatment persistence.<\/jats:p>","DOI":"10.3390\/jpm14111105","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:06:32Z","timestamp":1731571592000},"page":"1105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-1037","authenticated-orcid":false,"given":"Stefano","family":"Gentileschi","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-6881","authenticated-orcid":false,"given":"Carlo","family":"Cannistr\u00e0","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Damiani","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Carli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-6660","authenticated-orcid":false,"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni Di Dio Firenze Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-043X","authenticated-orcid":false,"given":"Fabrizio","family":"Cantini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Stefano Hospital, 59100 Prato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Niccoli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Stefano Hospital, 59100 Prato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-5568","authenticated-orcid":false,"given":"Caterina","family":"Baldi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7379-4732","authenticated-orcid":false,"given":"Andrea","family":"Delle Sedie","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.berh.2023.101857","article-title":"The association between comorbidities and disease activity in spondyloarthritis\u2014A narrative review","volume":"37","author":"Bosch","year":"2023","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2403935","DOI":"10.1155\/2018\/2403935","article-title":"Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies","volume":"2018","author":"Chyuan","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6983272","DOI":"10.1155\/2020\/6983272","article-title":"Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis","volume":"2020","author":"Gentileschi","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1759720X221090310","DOI":"10.1177\/1759720X221090310","article-title":"Effectiveness and safety of secukinumab in axial spondyloarthritis: A 24-month prospective, multicenter real-life study","volume":"14","author":"Ramonda","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/annrheumdis-2020-eular.5118","article-title":"FRI0272 Secukinumab Demonstrates a Consistent Safety Profile in Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis Over Long Term: Updated Pooled Safety Analyses","volume":"79","author":"Deodhar","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/annrheumdis-2020-eular.3197","article-title":"FRI0273 Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-Life Data from The Italian Lorhen Registry","volume":"79","author":"Favalli","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-023-00986-6","article-title":"The bone marrow side of axial spondyloarthritis","volume":"19","author":"Mauro","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sivera, F., N\u00fa\u00f1ez-Monje, V., Campos-Fern\u00e1ndez, C., Balaguer-Trull, I., Robustillo-Villarino, M., Aguilar-Zamora, M., Garijo-Bufort, M., L\u00f3pez-G\u00f3mez, J.M., Pe\u00f1a-Gonz\u00e1lez, C., and de la Morena, I. (2023). Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1156557"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Dorta, A., Le\u00f3n-Suarez, P., Pe\u00f1a, S., Hern\u00e1ndez-D\u00edaz, M., Rodr\u00edguez-Lozano, C., Gonz\u00e1lez-D\u00e1vila , E., Hern\u00e1ndez-Hern\u00e1ndez, M.V., and D\u00edaz-Gonz\u00e1lez, F. (2022). Association of Gender, Diagnosis, and Obesity with Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study. Front. Med., 8.","DOI":"10.3389\/fmed.2021.815881"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"152388","DOI":"10.1016\/j.semarthrit.2024.152388","article-title":"Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice","volume":"65","author":"Christiansen","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014A nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","article-title":"Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers\u2019 effectiveness in axial spondyloarthritis: Results of a prospective, multicentre study","volume":"77","author":"Etcheto","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Larid, G., Baudens, G., Tiemdjo-Djimaffo, G., Coquerelle, P., Goeb, V., Guyot, M.H., Marguerie, L., Maury, F., Veillard, E., and Houvenagel, E. (2024). Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-52016-4"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/11\/1105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:32:21Z","timestamp":1760113941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/11\/1105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jpm14111105"],"URL":"https:\/\/doi.org\/10.3390\/jpm14111105","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}